The estimated Net Worth of Gregory Alan Korbel is at least $308 Mille dollars as of 1 December 2021. Gregory Korbel owns over 27,500 units of Aprea Therapeutics stock worth over $143,828 and over the last 5 years he sold APRE stock worth over $163,811. In addition, he makes $0 as Vice President - Business Development at Aprea Therapeutics.
Gregory has made over 5 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 27,500 units of APRE stock worth $25,300 on 1 December 2021.
The largest trade he's ever made was selling 32,960 units of Aprea Therapeutics stock on 20 September 2021 worth over $163,811. On average, Gregory trades about 8,283 units every 56 days since 2019. As of 1 December 2021 he still owns at least 44,667 units of Aprea Therapeutics stock.
You can see the complete history of Gregory Korbel stock trades at the bottom of the page.
Dr. Gregory Alan Korbel Ph.D. serves as Vice President - Business Development of the Company. Dr. Korbel has 12 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Aprea, he was Director of Business Development and Operations at Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson in December 2015 and served as Director of Research Operations subsequent to the acquisition. In addition to consulting for venture capital and biotechnology firms, he formerly served as Senior Scientist at Invtirogen/Life Technologies. Dr. Korbel received an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in Chemistry from Harvard University and a B.A. from Vanderbilt University.
Gregory Korbel is 44, he's been the Vice President - Business Development of Aprea Therapeutics since 2016. There are 17 older and no younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... e John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: